SRPT News 24.40 Sarepta Therapeutics Inc (SRPT)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Sarepta Therapeutics Inc (SRPT) 24.40 $SRPT

Why Investors Need to Watch Sarepta Therapeutics Inc.
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Tue Apr 15, 8:30AM CDT
Sarepta is a popular stock in the Fool community, but its inestors have had a tough run lately, watching shares lose half of their value in the past six months. A late-stage trial failure by a competing drug from GlaxoSmithKline and Prosensa ...

Sarepta Therapeutics on Cusp of Huge Eteplirsen News
at The Street - Tue Apr 08, 1:34PM CDT
Sarepta executives met again with FDA officials in March to nail down a regulatory path for the Duchenne muscular dystrophy drug eteplirsen. The company has promised to update investors about the outcome of the FDA meeting, but without saying exactly...

Nasdaq stocks posting largest percentage increases
AP - Mon Apr 07, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:

Top Gainers Technical Data -- Research on BGC Partners, Sarepta Therapeutics, TripAdvisor, and LiveDeal
PR Newswire - Wed Apr 02, 6:59AM CDT
The US markets saw a positive sentiment on Tuesday, April 01, 2014, with the NASDAQ Composite closing at 4,268.04, up 1.64%, the Dow Jones Industrial Average ending the session at 16,532.61, up 0.46% and the S&P 500 edging 0.70% higher to finish the trading session at 1,885.52. During the session, gains in the Consumer Discretionary, Information Technology, and Industrials sectors positively impacted the broader market. A number of stocks saw large movements, including BGC Partners Inc. (NASDAQ: BGCP), Sarepta Therapeutics Inc. (NASDAQ: SRPT), TripAdvisor Inc. (NASDAQ: TRIP) and LiveDeal Inc. (NASDAQ: LIVE). Free technical research on BGCP, SRPT, TRIP and LIVE can be downloaded upon signing up at:

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against SAREPTA THERAPEUTICS, INC. and Its Board of Directors and a Lead Plaintiff Deadline of March 28, 2014
Business Wire - Wed Mar 26, 2:22PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Sarepta Therapeutics, Inc. ("Sarepta" or the "Company" (Nasdaq:SRPT) common stock between July 24, 2013 through November 12, 2013.

Sarepta Therapeutics to Present Company Overview at the 2014 Needham Healthcare Conference
Business Wire - Wed Mar 26, 7:30AM CDT
Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the 2014 Annual Needham Healthcare Conference in New York, NY on Tuesday, April 8, 2014 at 12:10 p.m. Eastern Time. Chris Garabedian, Sarepta's president and chief executive officer, will be the presenter.

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Sarepta Therapeutics, Inc. to Contact Brower Piven Before the March 28, 2014 Lead Plaintiff Deadline (SRPT)
GlobeNewswire - Sat Mar 22, 6:25AM CDT
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company" (Nasdaq:SRPT) common stock during the period between July 24, 2013 through November 12, 2013, inclusive (the "Class Period".

Prosensa Rises on Encouraging Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 4:20PM CDT
Shares of Prosensa rose following the announcement of encouraging data from a phase II study on drisapersen.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against SAREPTA THERAPEUTICS, INC. and Its Board of Directors and a Lead Plaintiff Deadline of March 28, 2014
Business Wire - Wed Mar 19, 3:33PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Sarepta Therapeutics, Inc. ("Sarepta" or the "Company" (Nasdaq:SRPT) common stock between July 24, 2013 through November 12, 2013.

Prosensa Muscular Dystrophy Data Send Stock Rising
at Investor's Business Daily - Tue Mar 18, 11:50AM CDT
Beleaguered biotech stock Prosensa (RNA) was up 8% in midday trading on the stock market today after the company reported new data on its Duchenne muscular dystrophy candidate late Monday. Earlier, Prosensa stock was up as much as 30%, to 8.80, a...

Prosensa Making the Best of Inconsistent Drisapersen Data
at The Street - Tue Mar 18, 10:03AM CDT
With its Big Pharma partner gone, Prosensa will probably try to conjure a good story to bring in front of the FDA.

Today’s Top Biotech Stories: Prosensa, Medivation, and Alcobra
Leo Sun, The Motley Fool - Motley Fool - Tue Mar 18, 8:26AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at this three top stocks -- Prosensa , ...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline -- SRPT
GlobeNewswire - Fri Mar 14, 2:15PM CDT
Pomerantz LLP has filed a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or the "Company" (Nasdaq:SRPT) and certain of its officers. The class action, filed in United States District Court, District of Massachusetts, and docketed under 14-cv-10225 is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Sarepta between July 24, 2013 and November 12, 2013 both dates inclusive (the "Class Period". This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

What Lies Ahead For Sarepta Therapeutics, Inc.?
Brian Orelli, The Motley Fool - Motley Fool - Fri Mar 14, 1:30PM CDT
Sarepta Therapeutics has been one roller coaster of a stock over the last year while waiting for the Food and Drug Administration to make up its mind about whether its Duchenne muscular dystrophy drug, eteplirsen, deserves an accelerated approval....

The 5 Most Hated Biotechs: Myriad, Sarepta, OncoMed, VIVUS, and MannKind
Brian Orelli, The Motley Fool - Motley Fool - Thu Mar 13, 5:30PM CDT
Not every company in biotech land is loved by investors. In fact, many biotechs top the list of companies with high short interest as a percentage of float. As of the end of February,  Myriad Genetics was the second-most shorted company as a...

'Fast Money' Recap: From Stocks to Bonds?
at The Street - Thu Mar 13, 4:00AM CDT
The trading panel discussed the S&P 500, copper and emerging markets.

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Sarepta Therapeutics, Inc. to Contact Brower Piven Before the March 28, 2014 Lead Plaintiff Deadline -- SRPT
GlobeNewswire - Fri Mar 07, 5:51PM CST
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company" (Nasdaq:SRPT) common stock during the period between July 24, 2013 through November 12, 2013, inclusive (the "Class Period".

The Nasdaq's 5 Most Hated Stocks
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 07, 5:16PM CST
I actually had to do some digging to come up with the date of April 7, 2000 as the last time the technology-heavy Nasdaq Composite closed at a higher point than it did earlier this week. The broader market has been the beneficiary of a strong...

Jim Cramer: Happy Birthday, You Bogus Bull Market
at The Street - Fri Mar 07, 10:22AM CST
You've rallied 177%, yet many don't seem to believe you exist.

Why Sarepta Therapeutics Inc. Might Have a Fighting Chance
Brian Orelli, The Motley Fool - Motley Fool - Tue Mar 04, 5:30PM CST
In November, it looked like Sarepta Therapeutics had very little chance of getting an accelerated approval for its Duchenne muscular dystrophy drug eteplirsen. The company said the Food and Drug Administration did a 180, from being open to...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cytonics Refines CYT-108 Trial Plan With Decade OA Data

Updated Category News Views 89

A Better Map Is Not a Working Drug Knee osteoarthritis has chewed up plenty of promising development plans because the disease moves at an aggravatingly uneven crawl. Cytonics has done something sensible before pushing deeper into CYT-108: it went back to long-term untreated patient data and asked which knees actually deteriorate fast enough for a trial to detect...

Continue Reading
Markel Elevates War Risk Expertise in London Market

Updated Category News Views 165

A Specialty Desk Gets Its Own Weather Vane War and political violence underwriting is not a corner of insurance where a fancy title change can be shrugged off. The ground shifts under the policyholder, the broker and the carrier without much warning, and a bad call can sit on a book for years. Markel Insurance has named Chloe Gordge Director of War and Political Violence...

Continue Reading
Nellie's 50% Booking Jump Reveals a Quieter Luxury

Updated Category News Views 134

Silicon Valley’s rich are apparently tired of performing wealth for strangers, and frankly, that tracks. Nellie’s 2027 forecast says its mostly tech-money clientele is moving past the old trophy case of private jets, famous resort towns, and suites priced like small houses. The prize now is privacy, a clean schedule, and somebody competent fixing the ugly little...

Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger

Updated Category News Views 249

A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...

Continue Reading
Sinopec’s Algerian Outreach Reveals a Patient Long Game

Updated Category News Views 109

Soft Power Does Not Run a Refinery, but It Matters A short video contest in Algiers will not move an oilfield schedule or settle a hydrocarbons negotiation. That is precisely why this Sinopec-backed event deserves a sober look rather than a chest-thumping one. On Nov. 15, Sinopec Group and the Chinese Embassy in Algeria co-hosted the final of their second youth cultural...

Continue Reading
Cold-Season Cleaning Advice Has a Practical Catch!

Updated Category News Views 53

Remote Controls Are Nobody’s First Suspect A television remote can make the rounds all evening and never see a cloth, which is precisely why Maid Brigade’s cold-and-flu-season reminder lands as common sense rather than revelation. The Scottsdale cleaning company is telling households to look past the usual kitchen counter and bathroom sink routine. Fair enough. People...

Continue Reading
BLLN Faces Fresh Questions After Short-Seller Report

Updated Category News Views 91

A six-percent air pocket is one thing; a disclosure mismatch is another beast entirely. BillionToOne shares fell on November 18 after short-seller Fuzzy Panda Research alleged the company had not disclosed meaningful regulatory scrutiny, including an alleged Tennessee matter in which regulators suspected fraud in 2024. That is an allegation from a short seller, not a...

Continue Reading
Veterans United Foundation Marks 15 Years of Giving

Updated Category News Views 62

A Milestone Measured in More Than Checks Fifteen years can turn a workplace charity into background noise, but this one plainly has not drifted into autopilot. Veterans United Foundation closed its 2026 anniversary campaign, called The Good Goes On, with $1.5 million directed to charitable organizations, 1,145 employee volunteers, and 2,680 hours of hands-on work. That is...

Continue Reading
APEC's Shared-Prosperity Message Needs More Detail

Updated Category News Views 50

Geese make handsome symbols, but markets cannot underwrite a metaphor. The Nov. 18, 2026 report from Xinhua News Agency looks back to remarks Chinese President Xi Jinping made 12 years ago, when he used swan geese to urge APEC economies toward greater cooperation and a new collective flight. Its present-day message is plainly hopeful: the APEC family is moving across the...

Continue Reading
HiTHIUM's 8-Hour Storage Pitch Faces Real Grid Tests

Updated Category News Views 89

Eight hours of stored electricity is where the sales brochure meets the ugly parts of the grid. HiTHIUM arrived at RE+ 2026 in Las Vegas, held November 17 through 19, with a broad storage pitch: systems ranging from two to eight hours, lithium-ion and sodium-ion chemistry, plus the software and validation work needed to make a battery plant behave when the local grid gets...

Continue Reading

Top 5 Most Recently Viewed Articles

Wind River Launches Innovative eLxr Pro for Modern Deployments

Updated Category News Views 314

Transforming Edge Computing with eLxr Pro Wind River, a leader in intelligent edge software solutions, has just launched a groundbreaking product, eLxr Pro. This is a commercial enterprise Linux distribution tailored to meet the rising demands of cloud-to-edge deployments, significantly improving performance and operational capabilities across a range of sectors. Meeting...

Continue Reading
VirnetX Welcomes Dr. Jamison as New Chief Technical Officer

Updated Category News Views 541

VirnetX Appoints a New Chief Technical Officer VirnetX Holding Corporation (NYSE: VHC) is excited to announce the appointment of Dr. John Anthony Jamison as their new Chief Technical Officer (CTO). His extensive background significantly bolsters the team’s expertise in secure communications technology. Dr. Jamison's Impressive Background Dr. Jamison brings a wealth of...

Continue Reading
NDEX Systems Enhances Advisor Workflows with New Technology

Updated Category News Views 188

Innovative Integration by NDEX Systems MONTREAL — NDEX Systems, a leader in multi-custodian data utility and wealth-management solutions, has recently unveiled a new integration that significantly enhances the advisor experience. This development introduces a sophisticated single sign-on (SSO) connection and a fully integrated client onboarding process with the Schwab...

Continue Reading
Transforming Agriculture: The Rise of Regenerative Practices

Updated Category News Views 239

The Rise of Regenerative Agriculture In the current agricultural landscape, regenerative agriculture has emerged as a crucial response to the pressing issues of climate change, soil degradation, and food security. This innovative farming method doesn't just optimize food production; it revitalizes ecosystems and offers economic advantages for farmers around the globe....

Continue Reading
Ericsson's Q2 2025 Performance Highlights and Future Strategies

Updated Category News Views 367

Financial Overview of Q2 2025 Ericsson has reported significant advancements in its financial performance for the second quarter of 2025. With operational excellence, the company has seen a remarkable 48% adjusted gross margin, marking a three-year high in adjusted EBITA margin. This reflects a strong commitment to strategic execution and operational improvements....

Continue Reading